Thus, EZH2 has been considered a bona fide therapeutic target in cancer therapies, and inhibitors targeting EZH2 have been increasingly developed, such as tazemetostat (EPZ-6438), valemetostat, CPI-0209 and CPI-1205 33-36. This evidence concerns the gene EZH2 and cancer.